Japan is pressing ahead with broader drug price cuts under its cost-effectiveness assessment (CEA) system, despite lingering questions over the…
BUSINESS
Fujifilm Adds Linker-Payload Capacity to Build One-Stop ADC CDMO Service
Fujifilm will install linker-payload manufacturing equipment at a group company plant in Japan, adding a key piece to its expanding domestic CDMO operations and paving the way for an end-to-end service for antibody drug conjugates (ADCs). The new equipment will…
To read the full story
Related Article
- Fujifilm Completes Major Biologics CDMO Plant in Toyama, Eyes 2027 Start-Up
December 25, 2025
- Fujifilm to Launch ADC-Focused CDMO Services First in Japan
November 7, 2025
- Fujifilm to Offer Small-Batch CDMO Services for Investigational mRNA Drugs from 2026
July 8, 2025
- Fujifilm to Launch Domestic Bio-CDMO Site in FY2026 to Bolster Vaccine Production
October 7, 2022
BUSINESS
- Mochida Lifts G-Lasta Biosimilar Shipment Curbs after Over 2 Years
November 4, 2026
- Espha Taps Korean Eylea Follow-On for First Biosimilar Foray
November 4, 2026
- Kyowa Kirin Won’t Stop Drug Launches over MFN Pricing: CEO
November 4, 2026
- Takara Bio, S-RACMO Finalize Cell Processing CDMO Transfer for January
November 4, 2026
- Roche Launches CDx for Takeda’s Elahere in Japan
November 4, 2026
Analysis of individual placements across 43 companies over the past 18 months paints a vivid picture of Japan’s evolving healthcare industry. This comprehensive snapshot illuminates current market demands, strategic shifts, and the enduring appeal of this pivotal Asian market.Rare Diseases…
Members of a key reimbursement policy panel on October 28 raised no objections to expanding drug makers’ access to deliberations…
Japan’s pharmaceutical industry asked the ruling Liberal Democratic Party (LDP) on October 29 to boost the country’s drug supply security…
Eli Lilly’s breast cancer drug Imulrio (imlunestrant) is finally joining Japan’s NHI price list on October 14, nearly 300 days…
Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…